Alnylam Pharmaceuticals Inc
XETRA:DUL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
A
|
Alnylam Pharmaceuticals Inc
XETRA:DUL
|
US |
|
P
|
Pioneer Natural Resources Co
F:PNK
|
US |
|
Cerro De Pasco Resources Inc
F:N8HP
|
CA |
|
Oriental Carbon & Chemicals Ltd
NSE:OCCL
|
IN |
|
N
|
Nesco Ltd
BSE:505355
|
IN |
|
S
|
Steppe Cement Ltd
XBER:ST9
|
MY |
|
F
|
Fielmann Group AG
DUS:FIE
|
DE |
|
A
|
Amazon.com Inc
XMUN:AMZ
|
US |
|
Elicio Therapeutics Inc
NASDAQ:ELTX
|
US |
|
F
|
Fomento de Construcciones y Contratas SA
DUS:FCC
|
ES |
|
Carter Bank and Trust
NASDAQ:CARE
|
US |
|
N
|
Nayax Ltd
NASDAQ:NYAX
|
IL |
|
Sumitomo Rubber Industries Ltd
OTC:SMTUF
|
JP |
|
Sollensys Corp
OTC:SOLS
|
US |
|
D
|
Doms Industries Ltd
BSE:544045
|
IN |
|
A
|
Avnet Inc
XBER:VNI
|
US |
|
A
|
Atlassian Corp
SWB:48D
|
US |
|
A
|
Alcoa Corp
ASX:AAI
|
US |
|
P
|
Pfizer Inc
DUS:PFE
|
US |
|
A
|
AG Mortgage Investment Trust Inc
NYSE:MITT
|
US |
|
N
|
Norsk Hydro ASA
DUS:NOH1
|
NO |
Bankruptcy Probability
Alnylam Pharmaceuticals Inc's probability of bankruptcy is Hidden . The solvency score is Hidden .
We take all the information about a company's solvency, such as how easily it can pay interest on outstanding debt, how much cash it has, the amount of debt, and more, and use it to estimate the probability of bankruptcy.
Solvency Ratios
Solvency Ratios Comparison
Alnylam Pharmaceuticals Inc Competitors
| Country | Company | Market Cap | D/E | D/A |
Interest Coverage |
Altman Z-Score |
Quick Ratio |
Current Ratio |
Cash Ratio |
||
|---|---|---|---|---|---|---|---|---|---|---|---|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
40.4B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
401.7B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
188.8B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
160.4B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
113.6B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
67.2B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
47.2B EUR |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
47.2B AUD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Alnylam Pharmaceuticals Inc's probability of bankruptcy is Hidden .
The probability of bankruptcy is estimated using credit risk models that assess financial health, debt levels, interest coverage, and other solvency indicators.
As of the latest report, Alnylam Pharmaceuticals Inc has total debt of 2.5B USD. This includes both short-term (0 USD) and long-term (2.5B USD) debt.
You can find a full breakdown on its Balance Sheet.
